Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00761241 · ClinicalTrials.gov registry record · Phase 2
Borderline Resectable Pancreatic Cancer: Gemcitabine/Docetaxel and Oxaliplatin Based Chemo/RT
A Phase 2 study, sponsored by Benaroya Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00761241: Completed Phase 2 study, sponsored by Benaroya Research Institute.
NCT00761241 is a Phase 2 study that has completed, run by Benaroya Research Institute. The registered enrollment target is 40 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00761241, a Phase 2 study, has completed, sponsored by Benaroya Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
This study is being conducted to find out what effects (good and bad) that a combination of treatment with chemotherapy, radiation therapy and surgery has on you and your pancreatic cancer. The chemotherapy drugs to be used: Gemcitabine, Docetaxel, Oxaliplatin, 5-FU and alpha-interferon. The goal is to decrease the size of the tumor, so that removal by surgery can be performed. Current treatments for this stage of pancreas cancer offer less than ideal results, with little opportunity for treatment with curative intent.
Interventions
- PROCEDURE Pancreaticoduodenectomy
- DRUG Gemcitabine, Docetaxel, 5FU, Oxaliplatin
- BIOLOGICAL Alpha-interferon
- RADIATION Abdominal/pelvic radiation therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2008-09 |
| Est. Completion | 2010-04 |
| Phase | Phase 2 |
What the finished NCT00761241 record still lists
NCT00761241 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (70% lower).
The record links to 0 conditions, and to 4 interventions - of which Pancreaticoduodenectomy is the first listed.
NCT00761241 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00761241 about?
NCT00761241 is a clinical study titled "Borderline Resectable Pancreatic Cancer: Gemcitabine/Docetaxel and Oxaliplatin Based Chemo/RT". This study is being conducted to find out what effects (good and bad) that a combination of treatment with chemotherapy, radiation therapy and surgery has on you and your pancreatic cancer. The chemotherapy drugs to be used: Gemcitabine, Docetaxel, Oxaliplatin, 5-FU and alpha-interferon. The goal is...
What is the current status of trial NCT00761241?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2008-09. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00761241?
The interventions under investigation include: Pancreaticoduodenectomy (PROCEDURE), Gemcitabine, Docetaxel, 5FU, Oxaliplatin (DRUG), Alpha-interferon (BIOLOGICAL), Abdominal/pelvic radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT00761241?
This trial is sponsored by Benaroya Research Institute, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00761241's enrollment target sits among peer trials
40 1362nd of 2000 higher than 542 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia